ISEE - IVERIC bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

IVERIC bio, Inc.

8 Sylvan Way
Parsippany, NJ 07054
United States
609 474 6755

Full Time Employees163

Key Executives

NameTitlePayExercisedYear Born
Mr. Glenn P. Sblendorio M.B.A.CEO & Director1.36M944.4k1956
Dr. Pravin U. Dugel M.D.Pres & Director984.82k59.66k1964
Mr. David F. Carroll M.B.A.Sr. VP, CFO & Treasurer725.55k827.86k1966
Mr. Keith Westby M.B.A.Sr. VP & COO701.68k1.7M1975
Mr. Christopher Paul SimmsSr. VP & Chief Commercial Officer715.01kN/A1975
Dr. Samir C. PatelCo-Founder and ConsultantN/AN/A1961
Dr. Xiao-Ping Dai Ph.D.Chief Technical OfficerN/AN/AN/A
Ms. Kathy GalanteSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Todd D.C. AndermanSr. VP, Chief Legal Officer & Corp. Sec.N/AN/AN/A
Ms. Amy R. SheehanSr. VP & Chief HR OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Corporate Governance

IVERIC bio, Inc.’s ISS Governance QualityScore as of June 1, 2023 is 5. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.